Literature DB >> 11883870

Comparison between buserelin and dexamethasone testing in the assessment of hirsutism.

T Re1, L Barbetta, C Dall'Asta, G Faglia, B Ambrosi.   

Abstract

Many hirsute women may present a form of functional ovarian hyperandrogenism (FOH), since they show an exaggerated 17-hydroxyprogesterone (17-OHP) response to GnRH agonists administration. As the failure of dexamethasone to reduce testosterone levels may be indicative of an ovarian source of androgen secretion, we evaluated the usefulness of dexamethasone suppression test, in comparison with buserelin challenge, in the assessment of hirsutism. Twenty-seven hirsute women (aged 15-42 yr) underwent ACTH and buserelin tests: 4 patients were heterozygotes for 21-OH deficiency and 8 patients were affected with FOH: 2 of the patients with hyperresponse to buserelin also had 21-hydroxylase deficiency. The results of the dexamethasone suppression test (2 mg/day for 7 days) were compared to those obtained after buserelin test. Basal T and delta4 levels (mean+/-SE) were higher than in controls (4.2+/-0.5 vs 2.2+/-0.2 nmol/l and 10.9+/-0.9 vs 5.9+/-0.6 nmol/l, p<0.02), while no differences were found in 17-OHP and DHEAS levels. A significant reduction (p<0.001) in T (1.8+/-0.4 nmol/l), delta4 (3.2+/-0.5 nmol/l) and DHEAS levels (2.4+/-0.3 micromol/l) was observed at the 3rd day of dexamethasone administration and no differences between sampling at 3rd, 5th and 7th day were found. Serum T was not suppressed in 6 cases, delta4 and DHEAS levels in 3 and 1 of them, respectively. Buserelin injection caused an excessive 17-OHP response in 8 patients, only 4 of them did not reduce T levels during dexamethasone. The sensitivity and specificity of the dexamethasone suppression test, with respect to the buserelin test, were 50% and 89%, respectively. In conclusion, 37% of hirsute patients had an abnormal responsiveness to buserelin and/or ACTH tests, indicating that hormonal investigations are mandatory. An ovarian origin of hirsutism was identified by buserelin test in 30% of patients and by dexamethasone in 22% of cases; only 4 of 8 patients showed concordant results to both tests. Therefore, buserelin challenge seems a more useful, cost-effective and less time consuming tool than dexamethasone administration in order to recognize the possible ovarian origin of hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883870     DOI: 10.1007/BF03343965

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

Review 1.  Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

Review 2.  Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome.

Authors:  E Carmina; R A Lobo
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

3.  Errors in the measurement of plasma free testosterone.

Authors:  W Rosner
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

Review 4.  Clinical review 56: Nonclassic adrenal hyperplasia: current concepts.

Authors:  R Azziz; D Dewailly; D Owerbach
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

5.  Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia.

Authors:  T Eldar-Geva; A Hurwitz; P Vecsei; Z Palti; A Milwidsky; A Rösler
Journal:  N Engl J Med       Date:  1990-09-27       Impact factor: 91.245

Review 6.  The polycystic ovary syndrome: pathogenesis and treatment.

Authors:  R Barnes; R L Rosenfield
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

7.  Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin.

Authors:  T J Wilke; D J Utley
Journal:  Clin Chem       Date:  1987-08       Impact factor: 8.327

8.  Source localization of androgen excess in adolescent girls.

Authors:  L Ibáñez; N Potau; M Zampolli; N Prat; M Gussinyé; P Saenger; E Vicens-Calvet; A Carrascosa
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

9.  Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.

Authors:  R B Barnes; R L Rosenfield; S Burstein; D A Ehrmann
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

10.  Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.

Authors:  R Azziz; V Black; G A Hines; L M Fox; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  1 in total

Review 1.  Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism.

Authors:  Eng-Loon Tng; Jeanne May May Tan
Journal:  J Endocr Soc       Date:  2020-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.